Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee CI, Fox P, Balakrishnar B, Balleine RL, Gao B, Provan P, Coulter S, Liddle C, Hui R, Wong M, Gurney H, Wilcken N.

Breast. 2019 May 6;46:52-57. doi: 10.1016/j.breast.2019.05.009. [Epub ahead of print]

PMID:
31082762
2.

Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry.

Lucas N, Robinson AB, Marcker Espersen M, Mahboob S, Xavier D, Xue J, Balleine RL, deFazio A, Hains PG, Robinson PJ.

J Proteome Res. 2019 Jan 4;18(1):399-405. doi: 10.1021/acs.jproteome.8b00684. Epub 2018 Nov 28.

PMID:
30444966
3.

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.

Gao B, Lu Y, Nieuweboer AJM, Xu H, Beesley J, Boere I, de Graan AM, de Bruijn P, Gurney H, J Kennedy C, Chiew YE, Johnatty SE, Beale P, Harrison M, Luccarini C, Conroy D, Mathijssen RHJ, R Harnett P, Balleine RL, Chenevix-Trench G, Macgregor S, de Fazio A.

Sci Rep. 2018 Jan 24;8(1):1508. doi: 10.1038/s41598-018-19590-w.

4.

Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.

Soon PS, Provan PJ, Kim E, Pathmanathan N, Graham D, Clarke CL, Balleine RL.

Clin Exp Metastasis. 2018 Feb;35(1-2):3-13. doi: 10.1007/s10585-017-9868-4. Epub 2017 Dec 6.

PMID:
29214365
5.

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A.

Gynecol Oncol. 2016 Sep;142(3):458-64. doi: 10.1016/j.ygyno.2016.06.023. Epub 2016 Jul 18.

PMID:
27444035
6.

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.

Fox P, Balleine RL, Lee C, Gao B, Balakrishnar B, Menzies AM, Yeap SH, Ali SS, Gebski V, Provan P, Coulter S, Liddle C, Hui R, Kefford R, Lynch J, Wong M, Wilcken N, Gurney H.

Clin Cancer Res. 2016 Jul 1;22(13):3164-71. doi: 10.1158/1078-0432.CCR-15-1470. Epub 2016 Feb 4.

7.

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.

Gao B, Russell A, Beesley J, Chen XQ, Healey S, Henderson M, Wong M, Emmanuel C, Galletta L, Johnatty SE, Bowtell D; Australian Ovarian Cancer Study Group, Haber M, Norris M, Harnett P, Chenevix-Trench G, Balleine RL, deFazio A.

Sci Rep. 2014 May 9;4:4669. doi: 10.1038/srep04669.

8.

The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.

Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL, Boyages J.

J Clin Pathol. 2014 Mar;67(3):222-8. doi: 10.1136/jclinpath-2013-201793. Epub 2014 Jan 8.

9.

Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.

Webster LR, Provan PJ, Graham DJ, Byth K, Walker RL, Davis S, Salisbury EL, Morey AL, Ward RL, Hawkins NJ, Clarke CL, Meltzer PS, Balleine RL.

Pathology. 2013 Dec;45(7):629-36. doi: 10.1097/PAT.0000000000000004.

PMID:
24247619
10.

Ki67 and proliferation in breast cancer.

Pathmanathan N, Balleine RL.

J Clin Pathol. 2013 Jun;66(6):512-6. doi: 10.1136/jclinpath-2012-201085. Epub 2013 Feb 22. Review.

PMID:
23436927
11.

Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing.

Pathmanathan N, Provan PJ, Mahajan H, Hall G, Byth K, Bilous AM, Balleine RL.

Breast. 2012 Dec;21(6):724-9. doi: 10.1016/j.breast.2012.09.001. Epub 2012 Oct 23.

PMID:
23099207
12.

High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.

Balleine RL, Wilcken NR.

Mol Diagn Ther. 2012 Aug 1;16(4):235-40. doi: 10.2165/11635470-000000000-00000. Review.

PMID:
22812573
13.

Electronic biorepository application system: web-based software to manage receipt, peer review, and approval of researcher applications to a biobank.

Khushi M, Carpenter JE, Balleine RL, Clarke CL.

Biopreserv Biobank. 2012 Feb;10(1):37-44. doi: 10.1089/bio.2011.0038. Epub 2012 Jan 17.

PMID:
24849752
14.

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD.

Breast Cancer Res Treat. 2011 Oct;129(3):659-74. doi: 10.1007/s10549-011-1632-x. Epub 2011 Jun 23.

PMID:
21698410
15.

Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.

Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J; Australian Ovarian Cancer Study Group, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A.

PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.

16.

Development of a data entry auditing protocol and quality assurance for a tissue bank database.

Khushi M, Carpenter JE, Balleine RL, Clarke CL.

Cell Tissue Bank. 2012 Mar;13(1):9-13. doi: 10.1007/s10561-011-9240-x. Epub 2011 Feb 18.

PMID:
21331789
17.

Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.

Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury EL, Bilous AM, Byth K; KConFab Investigators, Mann GJ.

Genes Chromosomes Cancer. 2010 Dec;49(12):1082-94. doi: 10.1002/gcc.20816.

PMID:
20815029
18.

HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.

Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, Faria P, Pereira E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Khanna KK, Cummings M, Chenevix-Trench G, Lakhani SR.

Breast Cancer Res. 2010;12(4):R46. doi: 10.1186/bcr2603. Epub 2010 Jul 6.

19.

Diagnostic evaluation of papillary lesions of the breast on core biopsy.

Pathmanathan N, Albertini AF, Provan PJ, Milliken JS, Salisbury EL, Bilous AM, Byth K, Balleine RL.

Mod Pathol. 2010 Jul;23(7):1021-8. doi: 10.1038/modpathol.2010.81. Epub 2010 May 14.

20.

A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast.

Pathmanathan N, Salisbury EL, Provan PJ, Bilous AM, Byth K, Milliken JS, Clarke CL, Balleine RL.

Pathology. 2010 Jan;42(1):28-36. doi: 10.3109/00313020903434355.

PMID:
20025477
21.

Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance.

Spurdle AB, Lakhani SR, Da Silva LM, Balleine RL; kConFab Investigators, Goldgar DE.

Hum Mutat. 2010 Feb;31(2):E1141-5. doi: 10.1002/humu.21181.

22.

Hormone-responsive model of primary human breast epithelium.

Graham JD, Mote PA, Salagame U, Balleine RL, Huschtscha LI, Clarke CL.

J Mammary Gland Biol Neoplasia. 2009 Dec;14(4):367-79. doi: 10.1007/s10911-009-9160-6. Epub 2009 Nov 21.

PMID:
19936891
23.

DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast.

Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL.

Endocrinology. 2009 Jul;150(7):3318-26. doi: 10.1210/en.2008-1630. Epub 2009 Apr 2.

24.

Molecular grading of ductal carcinoma in situ of the breast.

Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS.

Clin Cancer Res. 2008 Dec 15;14(24):8244-52. doi: 10.1158/1078-0432.CCR-08-0939.

25.

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.

Clin Cancer Res. 2008 Nov 1;14(21):6924-32. doi: 10.1158/1078-0432.CCR-07-5189.

26.

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701.

27.

Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.

Loughrey M, Provan PJ, Byth K; kConFab Investigators, Balleine RL.

Pathology. 2008 Jun;40(4):352-8. doi: 10.1080/00313020802035899.

PMID:
18446624
28.

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.

Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.

Clin Pharmacol Ther. 2007 Jul;82(1):33-40. Epub 2007 May 9.

PMID:
17495881
29.

Histopathological features of breast cancer in carriers of ATM gene variants.

Balleine RL, Murali R, Bilous AM, Farshid G, Waring P, Provan P, Byth K, Thorne H; kConFab Investigators, Kirk JA.

Histopathology. 2006 Nov;49(5):523-32.

PMID:
17064299
30.

Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab).

Am J Surg Pathol. 2006 Nov;30(11):1357-66.

PMID:
17063074
31.

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H.

J Clin Oncol. 2006 Jun 1;24(16):2448-55. Epub 2006 May 1.

PMID:
16651648
32.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res. 2006;8(1):R12. Epub 2006 Feb 13.

33.

MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, Defazio A.

Gynecol Oncol. 2006 Feb;100(2):239-46. Epub 2005 Oct 5.

PMID:
16213010
34.

Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.

Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A.

Int J Cancer. 2005 Dec 20;117(6):1049-54.

35.

Histopathologic indicators of breast cancer biology: insights from population mammographic screening.

Webster LR, Bilous AM, Willis L, Byth K, Burgemeister FC, Salisbury EL, Clarke CL, Balleine RL.

Br J Cancer. 2005 Apr 25;92(8):1366-71.

36.

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.

Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, Clarke CL, Balleine RL, Gurney H.

Clin Pharmacol Ther. 2005 Jan;77(1):33-42.

PMID:
15637529
37.

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H.

Clin Pharmacol Ther. 2004 Jun;75(6):529-38.

PMID:
15179407
38.

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.

Balleine RL, Earls PJ, Webster LR, Mote PA, deFazio A, Harnett PR, Clarke CL.

Int J Gynecol Pathol. 2004 Apr;23(2):138-44.

PMID:
15084842
39.

Targeting molecular mechanisms in cancer.

Balleine RL, Kefford RF.

ANZ J Surg. 2002 Oct;72(10):760-3. Review.

PMID:
12534393
40.

Tumour banks: providing human tissue for cancer research.

Balleine RL, Humphrey KE, Clarke CL.

Med J Aust. 2001 Sep 17;175(6):293-4. No abstract available.

PMID:
11665940
41.

Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma.

Mote PA, Balleine RL, McGowan EM, Clarke CL.

Hum Reprod. 2000 Aug;15 Suppl 3:48-56.

PMID:
11041221
42.

The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma.

Balleine RL, Fejzo MS, Sathasivam P, Basset P, Clarke CL, Byrne JA.

Genes Chromosomes Cancer. 2000 Sep;29(1):48-57.

PMID:
10918393
43.

Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle.

Mote PA, Balleine RL, McGowan EM, Clarke CL.

J Clin Endocrinol Metab. 1999 Aug;84(8):2963-71.

PMID:
10443705
44.

Expression of the oestrogen responsive protein pS2 in human breast cancer.

Balleine RL, Clarke CL.

Histol Histopathol. 1999 Apr;14(2):571-8. doi: 10.14670/HH-14.571. Review.

PMID:
10212819
45.

Coexpression of alternatively spliced estrogen and progesterone receptor transcripts in human breast cancer.

Balleine RL, Hunt SM, Clarke CL.

J Clin Endocrinol Metab. 1999 Apr;84(4):1370-7.

PMID:
10199781
46.

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.

Balleine RL, Earl MJ, Greenberg ML, Clarke CL.

Br J Cancer. 1999 Mar;79(9-10):1564-71.

47.

Characterization of a truncated progesterone receptor protein in breast tumors.

Yeates C, Hunt SM, Balleine RL, Clarke CL.

J Clin Endocrinol Metab. 1998 Feb;83(2):460-7.

PMID:
9467558
48.

Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content.

Graham JD, Balleine RL, Milliken JS, Bilous AM, Clarke CL.

Eur J Cancer. 1997 Sep;33(10):1654-60.

PMID:
9389930
49.

Progesterone receptor A and B protein expression in human breast cancer.

Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):93-8. Review.

PMID:
8603052
50.

Characterization of progesterone receptor A and B expression in human breast cancer.

Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL.

Cancer Res. 1995 Nov 1;55(21):5063-8.

Supplemental Content

Loading ...
Support Center